Pharmacogenomics in Oncology

Pharmacogenomics in oncology is distinctive because two genomes shape drug response: the patient's inherited (germline) genome, which governs how anticancer drugs are metabolized and how host tissues tolerate them, and the tumor's acquired (somatic) genome, which influences whether a drug acts on its target and whether resistance emerges. Germline variation in enzymes such as thiopurine S-methyltransferase, NUDT15, and dihydropyrimidine dehydrogenase is linked to the risk of severe toxicity from common chemotherapies, making this one of the most translated areas of pharmacogenomics.

Definition

Pharmacogenomics in oncology is the study of how heritable (germline) and tumor-acquired (somatic) genetic variation jointly determine the efficacy, resistance, and toxicity of anticancer therapy.

Scope

The entry covers the dual role of germline and somatic variation in cancer drug response, the major germline gene-drug relationships affecting chemotherapy toxicity (thiopurines, fluoropyrimidines, and tamoxifen activation), and the conceptual distinction between predicting host toxicity and predicting tumor response. It treats oncology pharmacogenomics as a conceptual topic and is not a source of dosing or treatment guidance.

Core questions

• How do germline and somatic variation differ in what they predict about cancer drug response?
• Which germline variants are linked to severe chemotherapy toxicity, and through what enzymes?
• How does tumor genotype shape efficacy and the emergence of resistance?
• Why is oncology among the most translated areas of clinical pharmacogenomics?

Key concepts

• Germline versus somatic variation
• TPMT and NUDT15 in thiopurine toxicity
• DPYD in fluoropyrimidine toxicity
• CYP2D6 and tamoxifen activation
• Host toxicity versus tumor response
• Acquired drug resistance

Mechanisms

Anticancer drug response in oncology is determined by two genomes acting through different routes. The germline genome controls the enzymes that activate, inactivate, and eliminate cytotoxic and targeted drugs, so inherited reduced-function variants can cause toxic accumulation of a drug or its active metabolites: low thiopurine S-methyltransferase or NUDT15 activity raises the risk of myelosuppression from thiopurines, reduced dihydropyrimidine dehydrogenase activity raises the risk of severe toxicity from fluoropyrimidines, and CYP2D6 activity governs conversion of tamoxifen to its active metabolite. The somatic genome of the tumor, by contrast, determines whether a drug's molecular target is present and active and whether resistance-conferring alterations arise during treatment. Predicting host toxicity therefore relies chiefly on germline genotyping, whereas predicting efficacy and resistance often depends on tumor (somatic) profiling; both layers must be considered to understand response in cancer therapy.

Clinical relevance

This topic helps clinicians and trainees understand why oncology distinguishes germline testing for toxicity risk from tumor profiling for efficacy, and why several germline gene-drug pairs are among the most actionable in pharmacogenomics. It is reference-educational, describing how cancer drug-response evidence is reasoned about, and is not a basis for individual dosing or treatment decisions.

Epidemiology

The germline pharmacogene variants relevant to chemotherapy toxicity vary in frequency across ancestral populations, which is why guidelines for thiopurines and fluoropyrimidines account for population-specific allele distributions; the somatic alterations relevant to efficacy vary by tumor type and individual tumor.

Evidence & guidelines

Oncology contains several of the best-supported clinical pharmacogenomic recommendations: implementation guidance addresses thiopurine dosing in relation to TPMT and NUDT15 genotype, fluoropyrimidine dosing in relation to DPYD genotype, and the influence of CYP2D6 on tamoxifen. These are curated by PharmGKB and translated by implementation consortia such as CPIC.

History

Oncology was an early and productive setting for clinical pharmacogenomics because cytotoxic drugs have narrow therapeutic windows and severe dose-limiting toxicities, so inherited differences in their metabolism had visible clinical consequences. Recognition of thiopurine S-methyltransferase deficiency and later NUDT15 and dihydropyrimidine dehydrogenase variants linked specific genotypes to toxicity risk, while the rise of tumor genome profiling added the somatic dimension that now defines much of cancer therapeutics.

Debates

Germline toxicity prediction versus somatic efficacy prediction

Cancer pharmacogenomics spans two distinct uses — germline testing to anticipate host toxicity and tumor profiling to predict efficacy and resistance — and how to integrate these conceptually and operationally in care is an ongoing discussion.

Key figures

• Mary Relling
• William Evans
• Matthias Schwab
• Matthew Goetz
• Teri Klein

Seminal works

• relling-2015
• evans-2003
• relling-2019

Frequently asked questions

Why does oncology pharmacogenomics involve two genomes?

The patient's inherited (germline) genome determines how anticancer drugs are metabolized and tolerated, while the tumor's acquired (somatic) genome determines whether a drug works and whether resistance develops, so both shape response.

Which germline genes are linked to chemotherapy toxicity?

Variants in TPMT and NUDT15 are linked to thiopurine toxicity, DPYD to fluoropyrimidine toxicity, and CYP2D6 activity affects activation of tamoxifen, making these among the most established germline gene-drug relationships in oncology.